Winslow Capital Management’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q3 | $1.06B | Buy |
913,455
+219,831
| +32% | +$259M | 3.82% | 6 |
|
|
2026
Q2 | $832M | Sell |
693,624
-63,962
| -8% | -$65.4M | 2.86% | 8 |
|
|
2026
Q1 | $697M | Buy |
757,586
+358
| +0% | +$363K | 2.72% | 8 |
|
|
2025
Q4 | $817M | Sell |
757,228
-19,905
| -3% | -$19M | 2.74% | 8 |
|
|
2025
Q3 | $593M | Sell |
777,133
-417,673
| -35% | -$311M | 1.96% | 18 |
|
|
2025
Q2 | $931M | Buy |
1,194,806
+54,522
| +5% | +$42.4M | 3.11% | 7 |
|
|
2025
Q1 | $942M | Buy |
1,140,284
+363,944
| +47% | +$303M | 3.76% | 7 |
|
|
2024
Q4 | $599M | Buy |
776,340
+5,227
| +0.7% | +$4.33M | 2.13% | 13 |
|
|
2024
Q3 | $683M | Buy |
771,113
+167,956
| +28% | +$151M | 2.45% | 9 |
|
|
2024
Q2 | $546M | Buy |
603,157
+39,109
| +7% | +$31.3M | 1.97% | 15 |
|
|
2024
Q1 | $439M | Sell |
564,048
-84,923
| -13% | -$60.4M | 1.65% | 21 |
|
|
2023
Q4 | $378M | Buy |
648,971
+2,094
| +0.3% | +$1.22M | 1.57% | 20 |
|
|
2023
Q3 | $347M | Buy |
646,877
+161,509
| +33% | +$83.2M | 1.65% | 22 |
|
|
2023
Q2 | $228M | Buy |
+485,368
| New | +$204M | 1.02% | 38 |
|
|
2021
Q1 | – | Sell |
-1,942,514
| Closed | -$328M | – | 67 |
|
|
2020
Q4 | $328M | Sell |
1,942,514
-417,948
| -18% | -$62.4M | 1.37% | 23 |
|
|
2020
Q3 | $349M | Sell |
2,360,462
-82,670
| -3% | -$12.8M | 1.56% | 19 |
|
|
2020
Q2 | $401M | Buy |
2,443,132
+745,802
| +44% | +$114M | 1.95% | 16 |
|
|
2020
Q1 | $235M | Buy |
+1,697,330
| New | +$233M | 1.44% | 26 |
|
|
2019
Q2 | – | Sell |
-1,741,194
| Closed | -$226M | – | 66 |
|
|
2019
Q1 | $226M | Buy |
1,741,194
+272,003
| +19% | +$33.1M | 1.22% | 35 |
|
|
2018
Q4 | $170M | Buy |
+1,469,191
| New | +$164M | 1.05% | 45 |
|
|
2018
Q2 | – | Sell |
-155
| Closed | -$12K | – | 98 |
|
|
2018
Q1 | $12K | Sell |
155
-2,135,934
| -100% | -$172M | ﹤0.01% | 70 |
|
|
2017
Q4 | $180M | Sell |
2,136,089
-1,674,453
| -44% | -$142M | 0.99% | 53 |
|
|
2017
Q3 | $326M | Buy |
3,810,542
+1,517,677
| +66% | +$124M | 1.76% | 22 |
|
|
2017
Q2 | $189M | Sell |
2,292,865
-1,583,103
| -41% | -$129M | 1% | 53 |
|
|
2017
Q1 | $326M | Buy |
3,875,968
+1,719,538
| +80% | +$138M | 1.56% | 25 |
|
|
2016
Q4 | $159M | Buy |
2,156,430
+2,156,413
| +12,684,782% | +$161M | 0.73% | 62 |
|
|
2016
Q3 | $1K | Buy |
+17
| New | +$1.36K | ﹤0.01% | 160 |
|
Other funds holding LLY
Winslow Capital Management's LLY Position: Q3 2026 in Review
Winslow Capital Management increased its Eli Lilly (LLY) stake by 32% in Q3 2026, buying an estimated $259M and bringing the position to 913,455 shares worth $1.06B. The position accounts for 3.82% of the portfolio, ranked #6.
Winslow Capital Management first reported a position in LLY in Q3 2016 and has held it in 27 quarters since. 4,624 funds tracked by Wall St. Rank hold LLY as of Q3 2026.
- Winslow Capital Management held 913,455 shares of Eli Lilly worth $1.06B as of Q3 2026.
- Winslow Capital Management bought 219,831 Eli Lilly shares in Q3 2026, an estimated $259M.
- Eli Lilly made up 3.82% of Winslow Capital Management's portfolio in Q3 2026, its #6 holding.
- Winslow Capital Management first reported a position in Eli Lilly in Q3 2016 and has held it in 27 quarters since.
- 4,624 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2026.
Based on Winslow Capital Management's 13F filing for Q3 2026, filed 12 Nov 2026.